We are live on ! Find out more
BSX icon

Boston Scientific

1,395 hedge funds and large institutions have $111B invested in Boston Scientific in 2024 Q3 according to their latest regulatory filings, with 164 funds opening new positions, 564 increasing their positions, 476 reducing their positions, and 76 closing their positions.

New
Increased
Maintained
Reduced
Closed

116% more first-time investments, than exits

New positions opened: 164 | Existing positions closed: 76

18% more repeat investments, than reductions

Existing positions increased: 564 | Existing positions reduced: 476

9% more capital invested

Capital invested by funds: $102B → $111B (+$8.86B)

6% more funds holding

Funds holding: 1,3171,395 (+78)

0% more funds holding in top 10

Funds holding in top 10: 3636 (0)

0.38% less ownership

Funds ownership: 90.27%89.89% (-0.38%)

30% less call options, than puts

Call options by funds: $661M | Put options by funds: $944M

Holders
1,395
Holders Change
+78
Holders Change %
+5.92%
% of All Funds
20.03%
Holding in Top 10
36
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.52%
New
164
Increased
564
Reduced
476
Closed
76
Calls
$661M
Puts
$944M
Net Calls
-$283M
Net Calls Change
-$257M
Name Holding Trade Value Shares
Change
Change in
Stake
TFA
451
Transamerica Financial Advisors
Florida
$5.16M -$174K -2,204 -3%
WG
452
Winton Group
United Kingdom
$5.14M +$4.34M +55,101 +877%
NB
453
Norinchukin Bank
Japan
$5.07M +$671K +8,508 +16%
VanEck Associates
454
VanEck Associates
New York
$5.06M +$700K +8,882 +18%
MGP
455
Metis Global Partners
California
$4.96M +$177K +2,248 +4%
TCM
456
Teza Capital Management
Illinois
$4.96M -$5.04M -63,934 -52%
KA
457
Kintegral Advisory
New York
$4.92M -$60.5K -768 -1%
DWM
458
Dakota Wealth Management
Florida
$4.84M +$588K +7,455 +15%
QC
459
Quadrature Capital
United Kingdom
$4.8M +$4.51M +57,259 New
AC
460
Armistice Capital
New York
$4.76M +$2.65M +33,555 +144%
SCM
461
Sandler Capital Management
New York
$4.71M +$336K +4,267 +8%
WAM
462
Weiss Asset Management
Massachusetts
$4.7M +$4.42M +56,027 New
LMIM
463
Lockheed Martin Investment Management
Maryland
$4.69M -$5.24M -66,520 -54%
SP
464
Saranac Partners
$4.68M -$337K -4,275 -7%
LWMM
465
Legacy Wealth Management (Mississippi)
Mississippi
$4.66M -$39K -495 -0.9%
TCM
466
Tandem Capital Management
New Jersey
$4.62M -$214K -2,715 -5%
NSEDCP
467
NJ State Employees Deferred Compensation Plan
New Jersey
$4.61M
FHB
468
First Hawaiian Bank
Hawaii
$4.57M -$108K -1,374 -2%
FTDI
469
First Trust Direct Indexing
Massachusetts
$4.55M +$671K +8,518 +19%
TWC
470
TD Waterhouse Canada
Ontario, Canada
$4.5M +$340K +4,308 +9%
EFM
471
E Fund Management
China
$4.49M +$3.88M +49,164 +1,115%
BPCE
472
Bank Pictet & Cie (Europe)
Germany
$4.35M -$2.16M -27,416 -35%
VIM
473
Vinva Investment Management
Australia
$4.34M -$510K -6,469 -11%
TPCW
474
TD Private Client Wealth
New York
$4.27M -$30.7K -389 -0.8%
OAC
475
OMERS Administration Corp
Ontario, Canada
$4.26M -$2.59M -32,800 -39%

BSX Hedge Fund Activity: Q3 2024 in Review

1,395 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Boston Scientific (BSX) for Q3 2024, worth a combined $111B — up 8.7% from $102B a quarter earlier.

Buyers outnumbered sellers: 164 funds opened new BSX positions and 76 closed out — a net gain of 88 holders — while 564 added to existing stakes and 476 trimmed.

The largest buyer was AustralianSuper, adding an estimated $206M. The largest seller was Fidelity Investments, cutting an estimated $494M.

  • 1,395 institutional investors held Boston Scientific (BSX) as of Q3 2024, up from 1,317 in Q2 2024.
  • Funds reported $111B of Boston Scientific stock for Q3 2024, up 8.7% quarter-over-quarter.
  • 164 funds opened new Boston Scientific positions in Q3 2024 and 76 closed out, a net change of +88 holders.
  • The largest Boston Scientific buyer in Q3 2024 was AustralianSuper, an estimated $206M added.
  • The largest Boston Scientific seller in Q3 2024 was Fidelity Investments, an estimated $494M sold.

Based on aggregated 13F filings for Q3 2024.